NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Overview of attention for article published in BMC Pulmonary Medicine, April 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 23,009 followers.

RT @ATXA_Ireland: NTP42 plays a key role in alleviating #PAH pathophysiology. Check out @ATXA_Ireland's new paper on #NTP42 in preclinical…

RT @ATXA_Ireland: NTP42 plays a key role in alleviating #PAH pathophysiology. Check out @ATXA_Ireland's new paper on #NTP42 in preclinical…

RT @ATXA_Ireland: NTP42 plays a key role in alleviating #PAH pathophysiology. Check out @ATXA_Ireland's new paper on #NTP42 in preclinical…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.